Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

NCT00553098 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Immunodeficiency Syndrome
Non-Cancer Diagnosis

Interventions

BIOLOGICAL: Alemtuzumab
PROCEDURE: Allogeneic Bone Marrow Transplantation
PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation
DRUG: Cyclosporine
DRUG: Fludarabine Phosphate
OTHER: Laboratory Biomarker Analysis
DRUG: Mycophenolate Mofetil
RADIATION: Total-Body Irradiation

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]
[object Object]